Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats

Xenobiotica

Volumn 39, Issue 2, 2009, Pages 113-124

  Miyaji, Y ^a   Kurihara, A ^a   Kamiyama, E ^a   Shiiki, T ^a   Kawai, K ^b   Okazaki, O ^a  

^a DAIICHI SANKYO CO   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Glycosaminoglycan; Hepatic uptake clearance; Osteoprotegerin; Pharmacokintics; Tissue distribution

Indexed keywords

DEXTRAN SULFATE; FUCOIDIN; HEPARIN; IODINE 125; OSTEOPROTEGERIN; RECOMBINANT HUMAN OSTEOPROTEGERIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FISCHER 344 RAT; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LIVER CLEARANCE; LIVER SINUSOID; NONHUMAN; RAT; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; DEXTRAN SULFATE; FEMALE; HEPARIN; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; LIVER; OSTEOPROTEGERIN; POLYSACCHARIDES; RATS; RATS, INBRED F344; RECOMBINANT PROTEINS;

RATTUS;

EID: 61649094233     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802590745     Document Type: Article

References (28)

1. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan, CR. 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. Journal of Bone and Mineral Research 16:348-360.
2. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, et al.. 2003. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887-892.
3. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan, CR. 2000. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Research 60:783-787.
4. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik, PJ. 2003. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. Journal of Bone and Mineral Research 18:852-858.
5. Cheng Z, Chen J, Quinn TP, Jurisson, SS. 2004. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Research 64:1411-1418.
6. Colin S, Jeanny JC, Mascarelli F, Vienet R, Al-Mahmood S, Courtois Y, Labarre J.. 1999. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Molecular Pharmacology 55:74-82.
7. Hepburn TW, Hart TK, Horton VL, Sellers TS, Tobia LP, Urbanski JJ, Shi W, Davis, CB. 2001. Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. Journal of Pharmacology and Experimental Therapeutics 298:886-893.
8. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh, PW. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Medicine 6:521-528.
9. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I., et al. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences, USA 96:3540-3545.
10. Ji ZS, Sanan DA, Mahley, RW. 1995. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. Journal of Lipid Research 36:583-592.
11. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.. 1997. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. Journal of Pharmacology and Experimental Therapeutics 283:520-527.
12. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan, CR. 2001. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295-4304.
13. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
14. Mochizuki S, Fujise N, Higashio K, Tsuda E.. 2002. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. Journal of Bone and Mineral Metabolism 20:14-20.
15. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan, CR. 1999. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. Journal of Bone and Mineral Research 14:1478-1485.
16. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann, CJ. 2005. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. Journal of Clinical Endocrinology and Metabolism 90:2964-2971.
17. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al.. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
18. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A.. 2002. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002-3007.
19. Takakura Y, Fujita T, Hashida M, Maeda H, Sezaki H.. 1989. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties. Journal of Pharmaceutical Sciences 78:219-222.
20. Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.. 2006. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochemical and Biophysical Research Communications 347:460-467.
21. Tomoyasu A, Goto M, Fujise N, Mochizuki S, Yasuda H, Morinaga T, Tsuda E, Higashio K.. 1998. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochemical and Biophysical Research Communications 245:382-387.
22. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K.. 1997. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications 234:137-142.
23. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K.. 1998. Characterization of structural domains of human osteoclastogenesis inhibitory factor. Journal of Biological Chemistry 273:5117-5123.
24. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y.. 1999. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 14:518-527.
25. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al. 1998b. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337.
26. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al. 1998a. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences USA 95:3597-3602.
27. Zierhut ML, Gastonguay MR, Martin SW, Vicini P, Bekker PJ, Holloway D, Leese PT, Peterson, MC. 2008. Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women. Journal of Pharmacokinetics and Pharmacodynamics 35:379-399.1
28. Zioncheck TF, Richardson L, DeGuzman GG, Modi NB, Hansen SE, Godowski, PJ. 1994. The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats. Endocrinology 134:1879-1887.